Abstract

Get Ready to LEAP: Advances in Automated Arrhythmia Detection for Next-Generation hiPSC-CM MEA Assays

Giovanna Defilippi, Sr. Field Applications Scientist, Axion BioSystems

Trends in cardiac safety testing, as exemplified by CiPA and JiCSA, emphasize a move beyond surrogate measures of proarrhythmia. The cardiomyocyte and multiwell microelectrode array (CM-MEA) assay offers an ideal approach to evaluate pre-arrhythmic indicators in vitro. Join Axion BioSystems to discuss the new Local Extracellular Action Potential (LEAP) for next-generation CM-MEA assays. The LEAP assay allows you to record extracellular action potential waveforms and characterize repolarization irregularities (e.g. EADs), label-free and in real-time.